TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27912955

Group type: EXPERIMENTAL
Intervention: Dance groups conducted by experienced dance teachers for 45 minutes, three times a week for 16 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Music appreciation and socialisation groups for 45 minutes, three times a week for 16 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dance groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dance groups and music groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severe Impairment Battery and Clinical Global Impression of Change
Number of subjects: 0
Study: 24352377

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 40
Study: 19152909

Group type: COMPARATOR
Intervention: Standard preparation (fluid restriction then nothing by mouth 12 hours before the procedure, water and simethicone at capsule ingestion)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standard preparation + 10 mg oral metoclopramide before the procedure
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Citramag + senna bowel-purgative regimen the evening before CE
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Citramag + senna + 10 mg metoclopramide before the procedure
Number of subjects: 150
Study: 15891596

Group type: EXPERIMENTAL
Intervention: Prokinetic therapy with cisapride (10 mg t.i.d.) after 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline conditions (before treatment)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 17
Study: 11568201

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 86

Group type: COMPARATOR
Intervention: No patellar resurfacing
Number of subjects: 86
Study: 9604732

Group type: EXPERIMENTAL
Intervention: Sodium auro-thiomalate
Number of subjects: 40
Study: 8111937

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study: 3292844

Group type: EXPERIMENTAL
Intervention: Intra-vaginal suppositories containing S. nigrescens maceration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nystatin suppositories
Number of subjects: 50
Study: 12472200

Group type: EXPERIMENTAL
Intervention: Dialysis treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uremic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biochemical analysis
Number of subjects: 0
Study: 29995693

Group type: EXPERIMENTAL
Intervention: Concurrent exercise (CEX) including 2 aerobic and 9 resistance exercises performed alternately in circuit order for 40 minutes at 60-70% heart rate reserve using body mass or fixed loads.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-exercise control (CONT) sessions.
Number of subjects: 16
Study: 26189007

Group type: EXPERIMENTAL
Intervention: Imatinib 200 mg single dose
Number of subjects: 24
Study: 24135979

Group type: EXPERIMENTAL
Intervention: F+GOS (galacto-oligosaccharide)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: F+HMO (human milk oligosaccharides)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: H+H (mother's own milk fortified with concentrated donor human milk product)
Number of subjects: 27

Group type: COMPARATOR
Intervention: H+B (mother's own milk fortified with bovine powdered fortifier)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: F+GOS
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: H+H
Number of subjects: 27
Study: 22863133

Group type: EXPERIMENTAL
Intervention: n-HAP paste (Renamel AfterBleach, Sangi Co., Ltd., Tokyo, Japan)
Number of subjects: 42

Group type: COMPARATOR
Intervention: zero-HAP (placebo)
Number of subjects: 42
Study: 19692142

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.6mg/m(2)) plus Pemetrexed (500mg/m(2)) on day 1 (Arm A)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500mg/m(2)) on day 1 (Arm B)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.6mg/m(2)) on days 1 and 8 (Arm C)
Number of subjects: 155
Study: 18608522

Group type: EXPERIMENTAL
Intervention: Diane35 (35 microg ethinyl estradiol plus 2 mg cyproterone acetate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diane35
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diane35 and Diane35/metformin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diane35/metformin
Number of subjects: 60
Study: 15650667

Group type: EXPERIMENTAL
Intervention: Immediate anterior stabilization plus rehabilitation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Immobilization followed by rehabilitation
Number of subjects: 40
Study: 12460869

Group type: EXPERIMENTAL
Intervention: yohimbine (3 mg IC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: urapidil (10 mg IC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Revascularization
Number of subjects: 46
Study: 10509773

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (10 microg/d for 3 months)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 191
Study: 8738770

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 3 mg/kg, 15 mg/kg, or 30 mg/kg administered once daily for 7 days
Number of subjects: 59
Study: 2016451

Group type: EXPERIMENTAL
Intervention: Ramp treadmill protocols
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cycle ergometer protocols
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ramp treadmill tests
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ramp cycle ergometer tests
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bruce treadmill tests
Number of subjects: 41

Group type: COMPARATOR
Intervention: 50 W/stage cycle ergometer tests
Number of subjects: 41
Study: 7102537

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg four times a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 12
Study: 31811686

Group type: EXPERIMENTAL
Intervention: Overheard praise for a classmate being smart (experimental condition)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-social information (control condition)
Number of subjects: 200
Study: 30644008

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA; Gleolan®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional microsurgery
Number of subjects: 0
Study: 30321275

Group type: EXPERIMENTAL
Intervention: Whole-grain orange maize (WGOM) muffins
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Refined orange maize (ROM) muffins
Number of subjects: 9

Group type: COMPARATOR
Intervention: Refined white maize (RWM) muffins
Number of subjects: 9
Study: 27013067

Group type: EXPERIMENTAL
Intervention: Same-size trephine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Oversize trephine
Number of subjects: 118
Study: 25136444

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 52
Study: 22290969

Group type: EXPERIMENTAL
Intervention: Cethromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 0
Study: 19641491

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17123633

Group type: EXPERIMENTAL
Intervention: Feature search task
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conjunction search task
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 40
Study: 15898977

Group type: EXPERIMENTAL
Intervention: Immunotherapy with depigmented glutaraldehyde-polymerized extracts (Group-A)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (Group-C)
Number of subjects: 53
Study: 12126265

Group type: EXPERIMENTAL
Intervention: Nebivolol 2.5-5 mg daily (n = 81)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Amlodipine 5-10 mg daily (n = 87)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 168

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 168
Study: 9508173

Group type: EXPERIMENTAL
Intervention: Recombinant IL‐2 9 x 10(6) IU/m2 daily by continuous intravenous infusion for 4 days, followed by IL‐2 1.6 x 10(6) IU/m2 daily for 10 days
Number of subjects: 21
Study: 7697845

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (1000 mg/d)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg/d)
Number of subjects: 216
Study: 2664696

Group type: EXPERIMENTAL
Intervention: Skin temperature biofeedback with daily home practice of relaxation-mental imagery techniques
Number of subjects: 31

Group type: COMPARATOR
Intervention: Attention-placebo condition
Number of subjects: 31
Study: 1071668

Group type: EXPERIMENTAL
Intervention: Alprenolol (200-400 mg, twice daily)
Number of subjects: 7
Study: 30564892

Group type: COMPARATOR
Intervention: Diagnostic immune risk score (dIRS) model
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Prognostic immune risk score (pIRS) model
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Integration of pIRS with clinical characteristics
Number of subjects: 940
Study: 28334661

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25308399

Group type: EXPERIMENTAL
Intervention: Training program in consultation skills for pediatric diabetes teams
Number of subjects: 0
Study: 22968811

Group type: EXPERIMENTAL
Intervention: Ketoconazole and St John's wort for 8 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose of ketoconazole after St John's wort induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of both drugs
Number of subjects: 0
Study: 21707136

Group type: EXPERIMENTAL
Intervention: Dissonance intervention
Number of subjects: 306

Group type: COMPARATOR
Intervention: Educational brochure control
Number of subjects: 306
Study: 19166687

Group type: EXPERIMENTAL
Intervention: Cypher stent
Number of subjects: 153

Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 153
Study: 17143135

Group type: EXPERIMENTAL
Intervention: Nurse practitioner plus usual care
Number of subjects: 236

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 236
Study: 12918144

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 40
Study: 10834423

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 534

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 534
Study: 9210007

Group type: EXPERIMENTAL
Intervention: Ceftriaxone monotherapy
Number of subjects: 26
Study: 8216696

Group type: EXPERIMENTAL
Intervention: Clomipramine (25 to 75 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 29
Study: 3549811

Group type: EXPERIMENTAL
Intervention: Topical 1% minoxidil
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topical 5% minoxidil
Number of subjects: 66

Group type: COMPARATOR
Intervention: Topical minoxidil (1% and 5%)
Number of subjects: 66
Study: 31269890

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU/day for 12 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 28586258

Group type: EXPERIMENTAL
Intervention: Tobacco counter-advertisements targeting smokers' brands
Number of subjects: 260

Group type: COMPARATOR
Intervention: Tobacco counter-advertisements targeting other brands
Number of subjects: 260
Study: 26922146

Group type: EXPERIMENTAL
Intervention: Duloxetine (40-60mg/day)
Number of subjects: 1555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 1555
Study: 24393129

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 78
Study: 22789665

Group type: EXPERIMENTAL
Intervention: Patient Journey Survey (PJS) method
Number of subjects: 92

Group type: COMPARATOR
Intervention: Current Accreditation Survey (CAS) method
Number of subjects: 92
Study: 19601782

Group type: EXPERIMENTAL
Intervention: PEG‐IFN (1.5 mcg/Kg/w) plus RBV (>=10.6 mg/kg/d) for 24-48 or 48-72 weeks depending on genotype
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TMA assay for HCV‐RNA
Number of subjects: 100
Study: 17617285

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 1 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 2 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 4 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 1 mg to 2 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 1 mg to 4 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Guanfacine extended-release (GXR) 2 mg to 4 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (AEs)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vital signs and ECG parameters
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Hematology and serum chemistry panels
Number of subjects: 52
Study: 12736156

Group type: EXPERIMENTAL
Intervention: Testosterone administration (600 mg/wk for 3 weeks)
Number of subjects: 0
Study: 11075768

Group type: EXPERIMENTAL
Intervention: 1 mg of vitamin K orally
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 8725470

Group type: EXPERIMENTAL
Intervention: 4% CO2/20.9% O2/balance N2 (hypercapnia trial)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Humidified room air (control trial)
Number of subjects: 8
Study: 1358233

Group type: EXPERIMENTAL
Intervention: Phenylephrine (2.4 micrograms/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thymoxamine (80 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thymoxamine co-administration with phenylephrine
Number of subjects: 0
Study: 4009935

Group type: EXPERIMENTAL
Intervention: Electrical acupuncture with Tokki pI 200 at 1 Hz during neuroleptic anesthesia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neuroleptic anesthesia composed of droperidol, fentanyl, and nitrous oxide (70%) supplemented by a muscle relaxant
Number of subjects: 14
Study: 3098804

Group type: EXPERIMENTAL
Intervention: Enzyme-containing dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoride dentifrice at 1100 ppm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoride paste (commercial)
Number of subjects: 0
Study: 31761964

Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic instrumental variable analysis
Number of subjects: 0
Study: 29641307

Group type: EXPERIMENTAL
Intervention: Somatosensory electrical stimulation (SES)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 28349386

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 56
Study: 26053169

Group type: EXPERIMENTAL
Intervention: Abdominal paracentesis drainage (APD)
Number of subjects: 255

Group type: COMPARATOR
Intervention: No abdominal paracentesis drainage (Control)
Number of subjects: 255
Study: 23350812

Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine 0.2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine 0.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine 0.8 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21080144

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of metformin and fluoxetine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 18071020

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) at 40 cm H(2)O
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E)
Number of subjects: 17
Study: 16584394

Group type: EXPERIMENTAL
Intervention: High-dose induction (CIFN 27->9 microg daily for 24 weeks, 9 microg t.i.w. for 24 weeks) with ribavirin 800 mg/day
Number of subjects: 103

Group type: COMPARATOR
Intervention: Low-dose treatment (CIFN 18 microg t.i.w. for 12 weeks, 9 microg t.i.w. for 36 weeks) with ribavirin 800 mg/day
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: High-dose induction
Number of subjects: 103

Group type: COMPARATOR
Intervention: Low-dose treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 103
Study: 12827364

Group type: EXPERIMENTAL
Intervention: Insertion into the anterior tibial muscle (Mu)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Insertion into the muscle including manipulation of the needle (DeQi)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Superficial insertion (SF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no needle stimulation)
Number of subjects: 14
Study: 11053512

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 94
Study: 9357879

Group type: EXPERIMENTAL
Intervention: Epidural epinephrine (100 microg in saline)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (8 microg/kg in saline)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 15
Study: 8263570

Group type: EXPERIMENTAL
Intervention: Geriatric Quality of Life Questionnaire (GQLQ)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rand Physical Function instrument
Number of subjects: 100

Group type: COMPARATOR
Intervention: Barthel Index
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GQLQ ADL domain
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GQLQ
Number of subjects: 100
Study: 4030539

Group type: EXPERIMENTAL
Intervention: Vancomycin alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vancomycin with aminoglycosides
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 34
Study: 30545420

Group type: EXPERIMENTAL
Intervention: Music therapy intervention (MTG), 30-45 minutes weekly sessions, average of 7 sessions
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CG), n=11
Number of subjects: 21
Study: 27522631

Group type: EXPERIMENTAL
Intervention: 100 mg/day spironolactone
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo (or continued low-dose spironolactone)
Number of subjects: 360
Study: 24970843

Group type: EXPERIMENTAL
Intervention: Specific exercise programme
Number of subjects: 97

Group type: COMPARATOR
Intervention: Unspecific exercises (control)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 22464071

Group type: EXPERIMENTAL
Intervention: Intermittent bladder catheterization (IC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Continuous indwelling Foley catheterization (CIF)
Number of subjects: 160
Study: 20171415

Group type: EXPERIMENTAL
Intervention: Pancrelipase delayed-release 12,000-lipase unit capsules
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 18242141

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1196
Study: 16025260

Group type: EXPERIMENTAL
Intervention: 30-minute consultation with the patient's GP and invitation to further GP follow-up
Number of subjects: 91
Study: 12938901

Group type: EXPERIMENTAL
Intervention: CD‐ROM
Number of subjects: 80

Group type: COMPARATOR
Intervention: Printed materials
Number of subjects: 80
Study: 11035615

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy with granulocyte-colony-stimulating factor (G-CSF)
Number of subjects: 21
Study: 8782425

Group type: EXPERIMENTAL
Intervention: Increased perceptual salience of dimensions on information boards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information constraint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 0
Study: 1623569

Group type: EXPERIMENTAL
Intervention: Isotonic saline (0.9% NaCl solution)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hypertonic saline (7.5% NaCl solution)
Number of subjects: 21
Study: 6370985

Group type: EXPERIMENTAL
Intervention: Nomifensine (average doses of 150 mg/day)
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Imipramine (average doses of 150 mg/day)
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1319
Study: 31594889

Group type: EXPERIMENTAL
Intervention: Web-based support (COPD Web) in addition to usual care, a pedometer, and a leaflet about the importance of physical activity.
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care, a pedometer, and a leaflet about the importance of physical activity.
Number of subjects: 144
Study: 27709794

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 26776677

Group type: EXPERIMENTAL
Intervention: Robotic hysterectomy
Number of subjects: 142

Group type: COMPARATOR
Intervention: Open laparotomy
Number of subjects: 142
Study: 25493035

Group type: EXPERIMENTAL
Intervention: True diet (exclusion diet based on food intolerance tests)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control diet (including food items inducing moderate-severe reactions)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control diet (after switch to true diet)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: True diet (after switch from control diet)
Number of subjects: 38
Study: 22294512

Group type: EXPERIMENTAL
Intervention: Hydroxyurea 20 mg/kg/day
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 21083190

Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinaprilat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinapril and Quinaprilat
Number of subjects: 0
Study: 17967675

Group type: EXPERIMENTAL
Intervention: parecoxib 20 mg (IV) twice daily (n = 211)
Number of subjects: 422

Group type: COMPARATOR
Intervention: placebo (IV) twice daily (n = 203)
Number of subjects: 422